Version history

{
  "session_id": "sess_hypdebate_h_0f025d94_20260426_164158",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "content": "\n\n## Critical Evaluation: PLCG2 Allosteric Modulation for TREM2-Dependent Microglial Dysfunction\n\n### Core Weaknesses\n\n**1. Therapeutic Direction Ambiguity**\nThe hypothesis assumes PLCG2 *enhancement* is beneficial, but this is unproven. TREM2 signaling demonstrates context-dependent biphasic effects—promoting survival under stress yet potentially driving harmful hyperactivation. A therapy that increases PLCG2 activity could exacerbate neuroinflammatory states. Conversely, PLCG2 gain-of-function variants cause autoinflammation (PLCγ2-P828L), suggesting excessive activity is pathological.\n\n**2. Incomplete Pathway Verification**\nThe claim that TREM2 → SYK → PLCG2 is direct remains biochemically undercharacterized in primary microglia. Most evidence derives from cell lines or overexpression systems. Alternative downstream effectors (phosphoinositide 3-kinases, MAPK cascades) may dominate in vivo.\n\n**3. Specificity Paradox**\nPLCG2 serves multiple receptors beyond TREM2—BCR, FcγR, IL-2R—which are essential for B cells, NK cells, and myeloid cells systemically. Allosteric modulation that hits PLCG"
}